Skip to main content

Table 2 PK parameters after a single dose of SCT200

From: Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study

Dose (mg/kg)

n

Cmax (μg/mL)

AUC0-∞ (h*μg/mL)

CL_obs (mL/h/kg)

T1/2 (h)

Tmax (h)a

Vz_obs (ml/kg)

0.5

3

7.7 (13.2)

216.7 (17.7)

2.3 (17.7)

17.6 (7.6)

2.5 (2.5–2.5)

58.7 (10.8)

1.0

3

15.8 (11.4)

665.7 (12.7)

1.5 (12.7)

20.0 (4.8)

2.7 (2.5–4.0)

43.3 (16.1)

2.0

3

36.7 (20.4)

2,048.8 (44.2)

1.0 (44.2)

36.7 (57.7)

2.5 (2.5–7.6)

51.7 (22.1)

4.0

4

74.6 (11.9)

8,037.3 (15.9)

0.5 (15.9)

52.9 (40.0)

5.2 (2.5–8.0)

37.9 (31.8)

6.0

6

109.0 (10.0)

13,176.4 (19.9)

0.5 (19.9)

67.2 (37.8)

2.5 (2.5–4.0)

44.1 (42.1)

8.0

3

186.7 (26.9)

27,216.0 (31.2)

0.3 (31.2)

75.9 (115.8)

2.5 (2.5–2.5)

32.2 (75.4)

  1. The results shown are geometric means (coefficient of variation of the geometric mean)
  2. AUC0-∞ area under the concentration–time curve from time zero to infinity, Cmax maximum plasma concentration, CL Clearance, T1/2 half-life, Tmax time to maximum plasma concentration, Vz volume of distribution, PK pharmacokinetic
  3. Tmax is shown as median (range)